How big is Aytu Biopharma, Inc.?

As of Jun 18, Aytu Biopharma, Inc. has a market capitalization of 12.16 million, with net sales of 69.22 million and a net profit of 1.08 million reported over the last four quarters. As of Jun 24, the company's shareholder's funds were 27.72 million, and total assets were 118.86 million.

Market Cap: <BR>As of Jun 18, Aytu Biopharma, Inc. has a market capitalization of 12.16 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: <BR>For the latest four quarters, Aytu Biopharma, Inc. reported net sales of 69.22 million and a net profit of 1.08 million.<BR><BR>Balance Sheet Snapshot: <BR>As of Jun 24, the company's shareholder's funds amounted to 27.72 million, while total assets were reported at 118.86 million.

What does Aytu Biopharma, Inc. do?

Aytu Biopharma, Inc. is a specialty pharmaceutical company focused on prescription products for primary care and pediatrics, with a market cap of $12.16 million and recent net sales of $18 million. Key financial metrics include a P/E ratio of 2.00 and a return on equity of 16.29%.

Overview:<BR>Aytu Biopharma, Inc. is a specialty pharmaceutical company that markets a portfolio of prescription products addressing primary care and pediatric markets, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 18 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 4 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 12.16 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 2.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.10 <BR>Return on Equity: 16.29% <BR>Price to Book: 0.35<BR><BR>Contact Details:<BR>Address: 373 Inverness Pkwy Ste 206, ENGLEWOOD CO: 80112-5898 <BR>Tel: ['1 720 4376580', '649 755 7412'] <BR>Fax: 1 302 6365454 <BR>Website: http://aytubio.com/

Should I buy, sell or hold Aytu Biopharma, Inc.?

Who are in the management team of Aytu Biopharma, Inc.?

As of March 2022, Aytu Biopharma, Inc.'s management team includes Mr. Joshua Disbrow as Chairman and CEO, with directors Mr. Steven Boyd, Mr. Ketan Mehta, and independent directors Mr. Gary Cantrell, Mr. Carl Dockery, and Mr. John Donofrio.

As of March 2022, the management team of Aytu Biopharma, Inc. includes Mr. Joshua Disbrow, who serves as the Chairman of the Board and Chief Executive Officer. The Board of Directors also features Mr. Steven Boyd and Mr. Ketan Mehta as Directors, along with independent directors Mr. Gary Cantrell, Mr. Carl Dockery, and Mr. John Donofrio.

Is Aytu Biopharma, Inc. overvalued or undervalued?

As of September 10, 2025, Aytu Biopharma, Inc. is fairly valued with a P/E ratio of 2, a Price to Book Value of 0.35, and an EV to EBITDA ratio of 2.23, outperforming some peers with negative P/E ratios, while its stock has recently outperformed the S&P 500 over the past week and month but lagged in the longer term.

As of 10 September 2025, the valuation grade for Aytu Biopharma, Inc. moved from expensive to fair. The company is currently fairly valued based on its metrics. The P/E ratio stands at 2, the Price to Book Value is 0.35, and the EV to EBITDA ratio is 2.23, indicating a low valuation relative to earnings and book value.<BR><BR>In comparison to its peers, Aytu Biopharma has a P/E ratio of 2.4637, while Eiger BioPharmaceuticals, Inc. and Biofrontera, Inc. show negative P/E ratios, suggesting that Aytu is in a better position among its risky counterparts. The company's stock has outperformed the S&P 500 over the past week and month, with returns of 3.04% and 7.73%, respectively, although it has lagged behind the index over the longer term, particularly in the 3-year and 5-year periods.

Is Aytu Biopharma, Inc. technically bullish or bearish?

As of August 14, 2025, Aytu Biopharma, Inc. shows a mildly bullish trend with supportive daily moving averages and weekly Bollinger Bands, though tempered by a mildly bearish MACD and bearish KST, while the stock has recently outperformed the S&P 500 but underperformed over the longer term.

As of 14 August 2025, the technical trend for Aytu Biopharma, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by daily moving averages indicating bullish momentum and weekly Bollinger Bands also showing bullish signals. However, the MACD on a weekly basis is mildly bearish, and the KST is bearish, which tempers the overall bullish outlook. The stock has outperformed the S&P 500 in the past week and month, with returns of 3.04% and 7.73% respectively, but has underperformed over the longer term, particularly in the 3-year and 5-year periods.